Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of AnaBios.

    Client Virtual Booth

    ANABIOS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    AnaBios
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego Science Center 3030 Bunker Hill Street, Suite 312 San Diego, CA 92109
    Telephone
    Telephone
    (858) 224-7360
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://anabios.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/anabios-corporation/
    Twitter
    Twitter
    https://twitter.com/anabioscorp

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NIH/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States

    Details:

    This award will support the execution of Investigational New Drug-enabling studies aimed at obtaining Food and Drug Administration approval for subsequent human dosing in a Phase 1 clinical study incliding ANB-504, a lead small molecule dual inhibitor of two sodium channels.


    Lead Product(s): ANB-504

    Therapeutic Area: Neurology Product Name: ANB-504

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: National Institutes of Health

    Deal Size: $1.7 million Upfront Cash: Undisclosed

    Deal Type: Funding September 30, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AnaBios and Orion Publish Scientific Article Describing Novel Cardiac Compound

    Details:

    AnaBios provided ex vivo data from human heart tissue to assess the pro-arrhythmic risk of the new NCX1.1 inhibitor, ORM-11372 (developed in Orion Pharma).


    Lead Product(s): ORM-11372

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: ORM-11372

    Highest Development Status: PreclinicalProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Orion Biotechnology

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search